Key Factor Supporting Global Gene Editing Market Development in 2025: Role Of Gene Editing In Battling Communicable Diseases

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Gene Editing Market Size By 2025?
The sector focused on gene editing has experienced swift expansion lately, projected to escalate its valuation from $8.82 billion in the year 2024 to $10.31 billion by 2025, reflecting a compound annual growth rate (CAGR) of 17.0%; this upward trajectory witnessed during the past period stems from the identification of the crispr-cas9 system, progress made in genetic sequencing technologies, significant achievements in the medical field, increased financial support for scientific investigations, and the burgeoning biotechnology industry.

How Big Is the Gene Editing Market Size Expected to Grow by 2029?
Anticipating substantial expansion, the market centered around gene editing technologies is projected to surge, culminating in a valuation of $20.62 billion by the year 2029, propelled by a consistent annual growth trajectory measured at 18.9%. This anticipated upswing through the projection timeframe is fundamentally driven by the widening scope of therapeutic uses, ongoing improvements in both accuracy and operational effectiveness, the increasing market penetration of gene therapies, advancements in agricultural suitability, and the maturation of regenerative medicine approaches. Key developments shaping this market over the coming years encompass the adoption of techniques enabling simultaneous multiple edits, the introduction of novel base editing methods, the progression of gene drives for population control mechanisms, the development of non-viral mechanisms for material delivery, and the increasing utilization of these tools for disease simulation and novel drug identification.

View the full report here:
https://www.thebusinessresearchcompany.com/report/gene-editing-global-market-report

Which Key Market Drivers Powering Gene Editing Market Expansion and Growth?
The surging incidence of transmissible ailments, which necessitate advanced methods for identification and remedy, is the primary force driving expansion within the gene editing market. These contagious illnesses, stemming from infectious entities like bacteria, viruses, or parasites capable of spreading between individuals, animals, or through environmental contact, are seeing gene editing innovations increasingly utilized to devise precise strategies for genetically pinpointing and neutralizing pathogens, thus bolstering both the control and proactive management of these diseases. As a concrete illustration, the World Economic Forum, an international non-governmental body headquartered in Switzerland, reported in 2023 that the spread of infections like influenza and the respiratory syncytial virus (RSV) has escalated post-pandemic; by February 2023 in the United States alone, influenza resulted in an estimated 24 million cases, accompanied by 260,000 hospital admissions and 16,000 fatalities. Furthermore, data from the World Health Organization indicated that in 2022, tuberculosis affected 10.6 million individuals worldwide, tragically causing 1.3 million deaths. Consequently, the challenges posed by communicable diseases are directly stimulating growth in the sphere of gene editing.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2486&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Gene Editing Market?
To secure an advantage within the gene editing landscape, prominent market participants are rolling out novel technological advancements, including a method leveraging specific cell-penetrating peptides that forecasts benefits exceeding existing protocols. This methodology furthermore holds the potential to fuel the creation of sophisticated cellular treatments aimed at malignancies and various other ailments. Illustratively, in the month of April 2023, Penn Medicine, a substantial American integrated hospital network, determined that viral protein fragments utilized for cellular entry could alternatively serve as highly effective, yet minimally toxic, carriers for delivering CRISPR-Cas gene editing components into both cells and their respective DNA nuclei. Researchers anticipate this novel methodology will prove especially valuable for precise alterations of T cells and other autologous cells intended for therapeutic applications, like CAR T (chimeric antigen receptor T cell) therapy, which involves engineering a patient's own immune cells for cancer treatment. This newly developed strategy for cell genetic modification suggests substantial gains in how quickly and effectively modifications can occur, alongside a decrease in harmful effects on the cells compared to established techniques.

What Are the Emerging Segments in the Gene Editing Market?
The gene editingmarket covered in this report is segmented -

1) By Technology: CRISPR; TALEN; ZFN
2) By Application: Animal Genetic Engineering; Plant Genetic Engineering; Cell Line Engineering
3) By End Users: Biotechnology; Pharmaceutical; Contract Research Organization

Subsegments:
1) By CRISPR: CRISPR-Cas9; CRISPR-Cas12; CRISPR-Cas13; CRISPR-based Gene Drives
2) By TALEN (Transcription Activator-Like Effector Nucleases): Custom TALENs; Commercial TALEN Kits
3) By ZFN (Zinc Finger Nucleases): Custom ZFNs; Commercial ZFN Kits

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=2486&type=smp

Who Are the Global Leaders in the Gene Editing Market?
Major companies operating in the gene editing market include AstraZeneca plc, Thermo Fisher Scientific Inc., Merck KGaA, GE Healthcare Life Sciences, Agilent Technologies Inc., Lonza Group AG, PerkinElmer Inc., Bio-Rad Laboratories Inc., Qiagen N.V., CRISPR Therapeutics, Promega Corporation, GenScript USA Inc., Integrated DNA Technologies Inc., Intellia Therapeutics Inc., DNA Script Inc., Dharmacon Inc., Precision Biosciences Inc., Editas Medicine Inc., OriGene Technologies Inc., Tecan Group Ltd., Sangamo Therapeutics Inc., Horizon Discovery Group plc, Addgene Inc., New England Biolabs Inc., Cellectis SA, Recombinetics Inc., Allele Biotechnology LLC, Transposagen Biopharmaceuticals Inc., Bluebird Bio Inc., Regeneron Pharmaceuticals Inc., Amsbio LLC, Creative Biogene Inc., Synthego Corporation, Beam Therapeutics Inc., Caribou Biosciences Inc., Inscripta Inc., Mammoth Biosciences Inc., Sangon Biotech (Shanghai) Co. Ltd., ToolGen Inc., Mirus Bio LLC

Which are the Top Profitable Regional Markets for the Gene Editing Industry?
North America was the largest region in the gene editing market in 2024. Western Europe was the second largest region in the global gene editing market share. The regions covered in the gene editing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2486

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.